Atlas Trials

Greg Durm, MD

4 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Greg Durm, MD

RecordFirmDate
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm (NCT04317534)Greg Durm, MD2020-05-05
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer (NCT03871153)Greg Durm, MD2019-08-02
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) (NCT03285321)Greg Durm, MD2017-09-15

Track Greg Durm, MD automatically

Every clearance here is in the API, with alerts when new ones post.